Assessment of bone lesions with 18 F-FDG PET/MRI in patients with nasopharyngeal carcinoma

Nucl Med Commun. 2023 Jun 1;44(6):457-462. doi: 10.1097/MNM.0000000000001682. Epub 2023 Mar 10.

Abstract

Purpose: The purpose of this study is to evaluate the role of 18 fluorodeoxyglucose ( 18 F) PET/MRI ( 18 F-FDG PET/MRI) for detecting bone metastasis in nasopharyngeal carcinoma (NPC).

Patients and methods: Between May 2017 and May 2021, 58 histologically proven NPC patients who underwent both 18 F-FDG PET/MRI and 99m Tc-MDP planar bone scintigraphy (PBS) for tumor staging were included. With the exception of the head, the skeletal system was classified into four groups: the spine, the pelvis, the thorax and the appendix.

Results: Nine (15.5 %) of 58 patients were confirmed to have bone metastasis. There was no statistical difference between PET/MRI and PBS in patient-based analysis ( P = 0.125). One patient with a super scan was confirmed to have extensive and diffuse bone metastases and excluded for lesion-based analysis. Of the 57 patients, all 48 true metastatic lesions were positive in PET/MRI whereas only 24 true metastatic lesions were positive in PBS (spine: 8, thorax: 0, pelvis: 11 and appendix: 5). PET/MRI was observed to be more sensitive than PBS in lesion-based analysis (sensitivity 100.0% versus 50.0 %; P < 0.001).

Conclusions: Compared with PBS for tumor staging of NPC, PET/MRI was observed to be more sensitive in the lesion-based analysis of bone metastasis.

MeSH terms

  • Bone Neoplasms* / diagnostic imaging
  • Bone Neoplasms* / secondary
  • Fluorodeoxyglucose F18
  • Humans
  • Magnetic Resonance Imaging
  • Nasopharyngeal Carcinoma / diagnostic imaging
  • Nasopharyngeal Neoplasms* / diagnostic imaging
  • Positron-Emission Tomography
  • Radiopharmaceuticals
  • Sensitivity and Specificity
  • Tomography, X-Ray Computed

Substances

  • Fluorodeoxyglucose F18
  • Radiopharmaceuticals